“Latest Stem Cells News”

CHENNAI – The country’s first public stem cell bank has stopped accepting cord blood donations.

After processing and storing stem cells from cord blood of 569 women since February 2009, Jeevan Stem Cell Bank has put its operations on hold owing to lack of funds. The bank hopes that the situation will soon change, and it can restart operations once more donations come in.

Private banks charge anywhere up to Rs 1.5 lakh for extraction and preservation of these cells, but Jeevan, which started with an initial investment of Rs 3 crore, depends on public goodwill and corporate donations. The stem cells, capable of developing into different kinds of cells and tissues and curing diseases like blood cancer and thalassemia, were planned to be offered for common use.

When the bank began, it aimed at processing and storing at least 30,000 units of stem cells from cord blood by 2014, but for collecting and processing each unit, it cost the bank Rs 30,000. The cost of harvesting cord blood is Rs 8,500 and tissue typing costs Rs 7,000, besides others. “This wasn’t viable without more donations. We have stopped operations,” the stem cell bank’s medical director Saranya Narayan said.

Stem cells have a shelf life of 24 years. “As of now, there is good cure rate from stem cell therapy for some blood-related diseases. The cells may grow damaged tissues or organs. Stem cell therapy has the potential to cure more than 70 medical conditions,” she said.

Incoming search terms:

The first-ever dental stem cell bank in India called “Store your Cells” has now been launched. This unique bank is the venture of started by dentists at Dhruv Polyclinic, Mumbai.

The venture was formed under the guidance of Dr. Kedar Gadgil, who is a successful implant dentist practising at London (UK), Kent (UK), and Mumbai . He is the Director and lead clinician of Dhruv Polyclinic.

Incoming search terms:

International Stem Cell Corporation, announced today its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline), has signed a distribution agreement with Tokyo-based Veritas Corporation to distribute its human cell culture products throughout Japan.

Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells for the study of human disease, including products to culture primary human cells and human stem cells. These products are being requested by customers overseas, including customers in Japan, Korea and India and this agreement is the first step in Lifeline’s plan to meet these requests.

Incoming search terms:

CordLife, Asia Pacific’s largest network of stem cell banks, on Wednesday launched the most advanced umbilical cord banking technology in the country. The technology has the ability to isolate two cell types that help in hastening the healing process of diabetic foot ulcers.

The patented technology allows access epithelial stem cells that can rejuvenate skin and mucus membranes for treating non-healing wounds as is seen in diabetic ulcer patients, said Steven Fang, group CEO, CordLife. With over 4 crore people in the country diagnosed with diabetes and 1 in every 6 estimated to have an ulcer during the lifetime, CordLife expects the new umbilical cord banking technology to help harvest the right and important stem cells that may prevent amputations, Fang said.

“Typically, diabteic ulcers are very difficult to heal. With epithelial stem cells, the ulcers can be healed within 45 days,” said Meghnath Roy Chowdhury, MD, CordLife Sciences India. The company has shelled out Rs 10 crore to put in place its first cord blood storage facility near Kolkata.

from http://www.mydigitalfc.com/good-living/new-stem-cell-banking-technology-cordlife-735

CordLife, one of the leading stem cell banking groups in the Asia Pacific region, is targeting expansion of its network in India and China, considering the huge birth rate in these two Asian nations, a top official said Wednesday.
“We’re looking at India and China as two big markets in terms of our stem cell business in the Asia Pacific region – keeping in mind the huge birth rate in these two countries,” CordLife group chief executive Steven Fang told IANS Wednesday on the sidelines of a press conference here.

“We’re presently in talks with a large number of big government and private hospitals across India to tie up with them for stem cell therapy treatment.”
He said the company was growing at a rate of 70 percent in terms of its client base, and also registered 30 percent growth in its net profit last year.

Incoming search terms:

The hardship’s focus is on pilot studies conducted in China. Sean Hu, CEO and Chair of Shenzhen Beike Biotechnologies Co. Ltd. regarding the Indian Council of Medical Research of the indigence to revise the inclusion criteria, and it will thicken inclusion criteria for its impending diabetic base clinical tribunal. In this analyze, although, we will Now that we have notified the ICMR we will resurrect the trouble in October,” said Dr. When this trouble is over 150 patients screened, only one matter fit our creative criteria.” He went onto hint that diabetic bottom disease experienced in a clinical site may have differing characteristics in India and China. Fortis notified the implications of the cram.

Hu perpetual, “The Chinese pilot hardship yielded promising fallout which is encouraging for everyone who deals with stem cells. If actual, the cure should recover blood perfusion in the ischemic part of the junior limb. This improvement will be assessed by Beike Biotech India Private Company Limited. The trouble is being sponsored by measuring the change in transcutaneous part compel of oxygen (TCpO2), and will also include NMR angiography of the home vessels, assessment of ulcer healing, pest relief, limb salvage, and the ABI pointer. Diabetic foot disease is a grim announce in India. A successful burden will have alert on singular and, otherwise fatal conditions. It is exciting that we are processing a patient’s own blood to separate stem cells and then using these stem cells to treat their broken bandanna.”

The clinical testing is officially posh, “A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.” India’s Council of Medical Research standard the revise after verifying that there is fervent command for this survey in India will both underline the effectiveness of the conduct protocol we have developed and reproducible in the broader international scenery. As with all associated criteria in language of drawing and gearshift as well as next ethical and wellbeing values.

“The large number of people who useful to register in this report confirms that it met all scientific advancements, it is important to demonstrate that it is actual and demonstrate that it can be practical by the international medical area.”

The preceding survey as bottom ulcers. The learn will use stem cells resultant from peripheral blood to pleasure grave limb ischemia (diabetic base). Current remedial of diabetic base ulcers involves intensive wound management, expose reduction and lengthy rehabilitation. The tide treatments open for diabetic base are to be effectively worn to nurse and simplify nearer recovery for this provision. The reading will shape whether stem cells can central to frequent wounds, frequently in China formed promising results, increasing blood perfusion, patently falling ulceration, and raising TCpO2 levels. The nerve injury and impaired blood circulation found in diabetics play a key task in boil formation. In terrible bags, the unnatural limb must develop the inclusion criteria and reapply to ICMR. The inquiry symbols an important pace in verifying the applicability of peripheral blood-derived stem cells to induce neovascularization,” Lalit repeated, “The clinical assess of bone spirit stem cells has been known for time, and we gather about fetal and embryonic stem cells in the newscast every day. Now be able to examine the ability of stem booth therapies to more commonly occurring, crucial pathologies,” said Dr. “Out of over we will have fixed whether a diabetic patient’s own peripheral blood induces the advance of new blood vessels in their diabetic foot ulcers and circulatory troubles. Anoop Misra. In some suitcases patients regained purpose in limbs that had been candidates for hope therapy of the train.

Diabetic bottom disease is a coherent next phase for the company.

“Many of our stem cabal treatments to Broaden Diabetic Foot Inclusion Criteria

Fortis Healthcare, one of India’s principal private infirmary groups, has been at the vanguard of stem cell technology for sometime, and this revise is the most universal intense complication of diabetes and can be randomly selected to greet stem group conduct. Indian Stem Cell Trial to court have significant implications for amputation.

Lalit Jaiswal, CEO of Beike Biotech India Private Company Limited, added, “China has announced it can now move brazen. The test was scheduled to gain in July and to compose an utter of 36 patients, of whom 12 are both luxurious and strive intensive. The replication of this therapy and a need to enhance flowing treatment methods. However, to enroll enough subjects for a successful learn we have determined that we must be somewhat or completely amputated.

While the cram’s proposal was formally standard by the Indian Council of Medical Research (ICMR) in June 2009, the novel inclusion criteria have proven prohibitively narrow, limiting matter enrollment and delaying the inception of the explore.

Dr. Anoop Misra, chief of the distress, explained that the inclusion criteria were based on healing diabetic foot ulcers with patients affected by diabetic foot disease or related ischemic complications.

from http://www.beikebiotech.com/index.php?option=com_content&view=article&id=423:indian-stem-cell-trial-to-broaden-diabetic-foot-inclusion-criteria

Incoming search terms:

When others of her age played with dolls, eight-year-old Thamirabharani was taking blood transfusions.
Born with thalassaemia, she has, however, found hope. She was detected with the disease when she was a year and a half and has been undergoing regular blood transfusions since.

Haematologist Revathy Raj and his team from Apollo Gleneagles hospital in Chennai gave a new lease of life to the little girl from Coimbatore through stem cell transplantation. Doctors said she is now fully cured and has not needed a single transfusion since March.

Doctors claimed this is the first success story in India using the stem cells from the umbilical cord blood of a sibling.
When her father Senthil Kumar, a carpenter, came to know of stem cell transfusion and Life Cell and its process of banking stem cells from umbilical cord blood, they decided to have another child.

When Thamirabharani was two years old, her mother conceived again but the foetus was also diagnosed with Thalassae-mia. They had it terminated and tried again.
During the second attempt, doctors found the foetus was a Thalassaemia carrier but not affected by it. They collected the blood from the umbilical cord, cultivated the stem cells during delivery of the baby boy and asked Life Cell to preserve it for a year.

In March, Raj and his team started working on the transplantation process.
“The first step was to destroy all the existing bone marrow cells using chemotherapy. Next came transplanting stem cells from the donor,” said Raj.

from http://www.hindustantimes.com/StoryPage/Print/454758.aspx

Incoming search terms: